The testing of the available mathematical model in an appropriate experimental system and its validation in clinical material are further steps towards clarifying the role of the Epo/EpoR system in PDAC and towards optimization of rhEpo-based treatments of anemic cancer patients. This evidence concerns the gene EPOR and cancer.